

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method for the treatment of cancerous cell growth mediated by RAF kinase, comprising administering a compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is  $-\text{NH}-\text{C}(\text{O})-\text{NH}-$ ,

A is a substituted moiety of up to 40 carbon atoms of the formula:  $-\text{L}-(\text{M}-\text{L}^1)_q$ , where L is a 5 or 6 membered cyclic structure bound directly to D,  $\text{L}^1$  comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and  $\text{L}^1$  contains 0-4 heteroatoms which are members of the group consisting of nitrogen, oxygen or and sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 heteroatoms which are members of the group consisting of nitrogen, oxygen or and sulfur,

wherein  $\text{L}^1$  is substituted by at least one ~~substituent selected from the group consisting of~~  $-\text{SO}_2\text{R}_x$ ,  $-\text{C}(\text{O})\text{R}_x$  or and  $-\text{C}(\text{NR}_y)$   $\text{R}_z$ ,

$\text{R}_y$  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing one or more heteroatoms which are N, S, or O selected from N, S and O and optionally halosubstituted, up to ~~per-halo~~ per-halosubstitution,

$\text{R}_z$  is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms which are N, S, or O selected from N, S and O and optionally substituted by halogen, hydroxy or a and carbon based substituents of up to 24 carbon atoms[5] which optionally ~~contain~~ contains one or more heteroatoms which are N, S, or O selected from N, S and O and is

are optionally substituted by halogen;

$R_x$  is independently chosen from  $R_z$  moieties or is  $R_z$  or  $NR_aR_b$  where  $R_a$  and  $R_b$  are

a) independently

i) hydrogen,

ii) a carbon based moiety of up to 30 carbon atoms optionally containing one or more heteroatoms which are selected from N, S or O and optionally substituted by halogen, hydroxy or a carbon based substituent substituents of up to 24 carbon atoms[5] which optionally ~~contain~~ contains one or more heteroatoms which are selected from N, S or O and is are optionally substituted by halogen, or

iii)  $-OSi(R_f)_3$  where  $R_f$  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing one or more heteroatoms which are N, S or O selected from N, S and O and optionally substituted by halogen, hydroxy or a carbon based substituent substituents of up to 24 carbon atoms[5] which optionally ~~contain~~ contains one or more heteroatoms which are N, S, or O selected from N, S and O and is are optionally substituted by halogen; or

b)  $R_a$  and  $R_b$  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are selected from N, S or O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are selected from N, S or O substituted by halogen, hydroxy or a carbon based substituent substituents of up to 24 carbon atoms[5] which optionally ~~contain~~ contains one or more heteroatoms which are N, S, or O selected from N, S and O and is are optionally substituted by halogen; or

c) one of  $R_a$  or  $R_b$  is  $-C(O)-$ , a  $C_1-C_5$  divalent alkylene group or a substituted  $C_1-C_5$  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the one or more substituents substituent(s) of the substituted  $C_1-C_5$  divalent alkylene group are ~~selected from the group consisting of~~ halogen, hydroxy, or a carbon based substituent substituents of up to 24 carbon atoms[5] which optionally ~~contain~~ contains one or

more heteroatoms which are N, S, or O selected from N, S and O and is are optionally substituted by halogen;

where B is substituted, L is substituted or  $L^1$  is additionally substituted, the one or more substituents are ~~selected from the group consisting of~~ halogen, up to per-halosubstitution per-halo, and  $W_n$ , where n is 0-3;

wherein each W is ~~independently selected from the group consisting of~~ -CN,  $-CO_2R^7$ ,  $-C(O)NR^7R^7$ ,  $-C(O)R^7$ ,  $-NO_2$ ,  $-OR^7$ ,  $-SR^7$ ,  $-NR^7R^7$ ,  $-NR^7C(O)OR^7$ ,  $-NR^7C(O)R^7$ ,  $-Q-Ar$ , or a and carbon based ~~moiety moieties~~ of up to 24 carbon atoms[5] optionally containing one or more heteroatoms which are N, S, or O selected from N, S and O and optionally substituted by one or more substituents which are ~~independently selected from the group consisting of~~ -CN,  $-CO_2R^7$ ,  $-C(O)R^7$ ,  $-C(O)NR^7R^7$ ,  $-OR^7$ ,  $-SR^7$ ,  $-NR^7R^7$ ,  $-NO_2$ ,  $-NR^7C(O)R^7$ ,  $-NR^7C(O)OR^7$  or and halogen up to per-halosubstitution per-halo; with each  $R^7$  independently being selected from H or a carbon based moiety of up to 24 carbon atoms[5] optionally containing one or more heteroatoms which are N, S, or O selected from N, S and O and optionally substituted by halogen,

wherein Q is -O-, -S-,  $-N(R^7)$ -,  $-(CH_2)_m$ -,  $-C(O)$ -,  $-CH(OH)$ -,  $-(CH_2)_mO$ -,  $-(CH_2)_mS$ -,  $-(CH_2)_mN(R^7)$ -,  $-O(CH_2)_m-CHX^a$ -,  $-CX^a_2$ -,  $-S(CH_2)_m$ - or and  $-N(R^7)(CH_2)_m$ -, where m= 1-3, and  $X^a$  is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are members ~~selected from the group consisting of~~ nitrogen, oxygen or and sulfur, which is optionally substituted by halogen, up to per-halosubstitution, and optionally substituted by  $Z_{n1}$ , wherein  $n1$  is 0 to 3 and each Z is ~~independently selected from the group consisting of~~ -CN,  $-CO_2R^7$ ,  $-C(O)R^7$ ,  $-C(O)NR^7R^7$ ,  $-NO_2$ ,  $-OR^7$ ,  $-SR^7$ ,  $-NR^7R^7$ ,  $-NR^7C(O)OR^7$ ,  $-NR^7C(O)R^7$ , or and a carbon based moiety of up to 24 carbon atoms[5] optionally containing one or more heteroatoms which are N, S, or O selected from N, S and O and optionally substituted by one or more substituents which are ~~selected from the group consisting of~~ -CN,  $-CO_2R^7$ ,  $-COR^7$ ,  $-C(O)NR^7R^7$ ,  $-OR^7$ ,  $-SR^7$ ,  $-NO_2$ ,  $-NR^7R^7$ ,  $-NR^7C(O)R^7$ , or and  $-NR^7C(O)OR^7$ , with each  $R^7$  being independently as defined above.

2. (Currently Amended) A method as in claim 1 wherein:

R<sub>y</sub> is hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, C<sub>7-24</sub> aralkyl, C<sub>7-24</sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, substituted C<sub>6</sub>-C<sub>14</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, substituted C<sub>7-24</sub> alkaryl or substituted C<sub>7</sub>-C<sub>24</sub> aralkyl, where R<sub>y</sub> is a substituted group, it is substituted by halogen up to ~~per-halo~~ per-halosubstitution,

R<sub>z</sub> is hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl having 0-3 which are N, S or O heteroatoms, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3</sub>-C<sub>12</sub> hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from S, N and O~~, C<sub>7-24</sub> alkaryl, C<sub>7-24</sub> aralkyl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>6</sub>-C<sub>14</sub> aryl, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from S, N and O~~, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from S, N and O~~, substituted C<sub>7-24</sub> alkaryl or substituted C<sub>7</sub>-C<sub>24</sub> aralkyl where R<sub>z</sub> is a substituted group, it is substituted by halogen up to ~~per-halosubstitution~~ per-halo, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to ~~per-halosubstituted~~ per-halo alkyl, C<sub>6</sub>-C<sub>12</sub> halosubstituted aryl up to ~~per-halosubstituted~~ per-halo aryl, C<sub>3</sub>-C<sub>12</sub> halosubstituted cycloalkyl up to ~~per-halosubstituted~~ per-halo cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, halosubstituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to ~~per-halosubstituted~~ per-halo hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from O, N and S~~, halosubstituted C<sub>7</sub>-C<sub>24</sub> aralkyl up to ~~per-halosubstituted~~ per-halo aralkyl, halosubstituted C<sub>7</sub>-C<sub>24</sub> alkaryl up to ~~per-halosubstituted~~ per-halo alkaryl, and -C(O)R<sub>g</sub>,

R<sub>a</sub> and R<sub>b</sub> are,

a) independently

i) hydrogen,

ii) a carbon based moiety which is selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, C<sub>3-12</sub> C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S, O selected from N, S and O, C<sub>7-24</sub> aralkyl, C<sub>7-24</sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from N, S and O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from N, S and O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where R<sub>a</sub> or R<sub>b</sub> are substituted, the substituents are substituted by halogen up to per-halosubstituted per-halo, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, S and N, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted per-halo alkyl, C<sub>6-12</sub> halosubstituted aryl up to per-halosubstituted per-halo aryl, C<sub>3-12</sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O selected from N, S and O, up to per-halosubstituted per-halo cycloalkyl, halosubstituted C<sub>3-12</sub> hetaryl up to per-halosubstituted per-halo heteroaryl, halosubstituted C<sub>7-24</sub> aralkyl up to per-halosubstituted per-halo aralkyl, halosubstituted C<sub>7-24</sub> alkaryl up to per-halosubstituted per-halo alkaryl, or and -C(O)R<sub>g</sub> ; or

iii) -OSi(R<sub>f</sub>)<sub>3</sub> where R<sub>f</sub> is hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, S and N, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from O, S and N, C<sub>7-24</sub> aralkyl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, S and N, substituted C<sub>3-12</sub> heteroaryl having 1-3 heteroatoms which are N, S or O selected from O, S, and N, substituted C<sub>6-12</sub> aryl, or and substituted C<sub>7-24</sub> alkaryl,

where  $R_f$  is a substituted group it is substituted halogen up to per-halosubstitution ~~per~~ ~~halo~~, hydroxy,  $C_{1-10}$  alkyl,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~,  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S and O ~~selected from N, S and O~~,  $C_{1-10}$  alkoxy,  $C_{6-12}$  aryl,  $C_7-C_{24}$  alkaryl,  $C_7-C_{24}$  aralkyl,  $C_{1-6}$  halosubstituted alkyl up to per-halosubstituted ~~per halo~~ alkyl,  $C_6-C_{12}$  halosubstituted aryl up to per-halosubstituted ~~per halo~~ aryl,  $C_3-C_{12}$  halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, up to per-halosubstituted ~~per halo~~ cycloalkyl, halosubstituted  $C_3-C_{12}$  hetaryl up to per-halosubstituted ~~per halo~~ heteroaryl, halosubstituted  $C_7-C_{24}$  aralkyl up to per-halosubstituted ~~per halo~~ aralkyl, halosubstituted  $C_7-C_{24}$  alkaryl up to per-halo substituted ~~per halo~~ alkaryl, or and  $-C(O)R_g$ ,

or

b)  $R_a$  and  $R_b$  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~ with substituents which are selected from the group consisting of halogen up to per-halosubstitution ~~per halo~~, hydroxy,  $C_{1-10}$  alkyl,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from O, S and N~~,  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O ~~selected from N, S and O~~,  $C_{1-10}$  alkoxy,  $C_{6-12}$  aryl,  $C_7-C_{24}$  alkaryl,  $C_7-C_{24}$  aralkyl, halosubstituted  $C_{1-6}$  alkyl up to per-halosubstituted ~~per halo~~ alkyl, halosubstituted  $C_6-C_{12}$  aryl up to per-halosubstituted ~~per halo~~ aryl, halosubstituted  $C_3-C_{12}$  cycloalkyl having 0-3 heteroatoms which are N, S or O ~~selected from N, S and O~~, up to per-halosubstituted ~~per halo~~ cycloalkyl, halosubstituted  $C_3-C_{12}$  hetaryl up to per-halosubstituted ~~per halo~~ heteroaryl, halosubstituted  $C_7-C_{24}$  aralkyl up to per-halosubstituted ~~per halo~~ aralkyl, halosubstituted  $C_7-C_{24}$  alkaryl up to per-halosubstituted ~~per halo~~ alkaryl, or and  $-C(O)R_g$ ,

or

c) one of  $R_a$  or  $R_b$  is  $-C(O)-$ , a  $C_1-C_5$  divalent alkylene group or a substituted  $C_1-C_5$  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5

members,

wherein the substituents of the substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group are selected from the group consisting of halogen, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, S and N, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted per-halo alkyl, C<sub>6</sub>-C<sub>12</sub> halosubstituted aryl up to per-halosubstituted per-halo aryl, C<sub>3</sub>-C<sub>12</sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O selected from N, S and O, up to per-halosubstituted per-halo cycloalkyl, halosubstituted C<sub>3</sub>-C<sub>12</sub> heteroaryl hetaryl up to per-halosubstituted per-halo heteroaryl, halosubstituted C<sub>7</sub>-C<sub>24</sub> aralkyl up to per-halosubstituted per-halo aralkyl, halosubstituted C<sub>7</sub>-C<sub>24</sub> alkaryl up to per-halosubstituted per-halo alkaryl, or and -C(O)R<sub>g</sub>,

where R<sub>g</sub> is C<sub>1-10</sub> alkyl; -CN, -CO<sub>2</sub>R<sub>d</sub>, -OR<sub>d</sub>, -SR<sub>d</sub>, -NO<sub>2</sub>, -C(O) R<sub>e</sub>, -NR<sub>d</sub>R<sub>e</sub>, -NR<sub>d</sub> C(O)OR<sub>e</sub> or and -NR<sub>d</sub> C(O)R<sub>e</sub>, or and R<sub>d</sub> and R<sub>e</sub> are independently selected from the group consisting of hydrogen, C<sub>1-10</sub>, alkyl, C<sub>1-10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, N and S, C<sub>6-12</sub> aryl, C<sub>3</sub>-C<sub>12</sub> hetaryl with 1-3 heteroatoms which are N, S or O selected from O, N and S and C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>7</sub>-C<sub>24</sub> alkaryl, up to per-halosubstituted per-halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted per-halo substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, N and S, up to per-halosubstituted per-halo substituted C<sub>6</sub>-C<sub>14</sub> aryl, up to per-halosubstituted per-halo substituted C<sub>3</sub>-C<sub>12</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from O, N, and S, halosubstituted C<sub>7</sub>-C<sub>24</sub> alkaryl up to per-halosubstituted per-halo alkaryl, or and up to per-halosubstituted per-halo substituted C<sub>7</sub>-C<sub>24</sub> aralkyl,

W is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -C(O)-R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkenoyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, S and N, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>3</sub>-C<sub>12</sub> heteroaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, substituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted

C<sub>1</sub>-C<sub>10</sub> alkoxy, substituted C<sub>2</sub>-C<sub>10</sub> alkenyl, substituted C<sub>1</sub>-C<sub>10</sub> alkenoyl, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, N and S, substituted C<sub>6</sub>-C<sub>12</sub> aryl, substituted C<sub>3</sub>-C<sub>12</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, substituted C<sub>7</sub>-C<sub>24</sub> aralkyl, substituted C<sub>7</sub>-C<sub>24</sub> alkaryl, substituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, or and -Q-Ar;

R<sup>7</sup> is independently ~~selected from~~ H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkenoyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, S and N, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, C<sub>7</sub>-C<sub>14</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, up to per-halosubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, N and S, up to per-halosubstituted C<sub>6</sub>-C<sub>14</sub> aryl, up to per-halosubstituted C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, up to per-halosubstituted C<sub>7</sub>-C<sub>24</sub> aralkyl, up to per-halosubstituted C<sub>7</sub>-C<sub>24</sub> alkaryl, or and up to per-halosubstituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl; and

each Z is independently ~~selected from the group consisting of~~ -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkenoyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, N and S, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S, substituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted C<sub>1</sub>-C<sub>10</sub> alkoxy, substituted C<sub>2</sub>-C<sub>10</sub> alkenyl, substituted C<sub>1</sub>-C<sub>10</sub> alkenoyl, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O selected from O, N and S, substituted C<sub>6</sub>-C<sub>12</sub> aryl, substituted C<sub>7</sub>-C<sub>24</sub> alkaryl, substituted C<sub>7</sub>-C<sub>24</sub> aralkyl or and substituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms which are N, S or O selected from O, N and S;

wherein if Z is a substituted group, the one or more substituents are ~~selected from the group consisting of~~ -CN, -CO<sub>2</sub>R<sup>7</sup>, -COR<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, or and -NR<sup>7</sup>C(O)OR<sup>7</sup>.

3. (Currently Amended) A method as in claim 2 ± wherein M is one or more bridging groups which are selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen and R<sup>7</sup> is as defined in claim 2 ±.

4. Cancelled

5. Cancelled

6. (Currently Amended) A method of claim 2 ± wherein B of Formula I is an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl, a phenyl group substituted by one or more substituents which are a substituent selected from the group consisting of halogen or and W<sub>n</sub> W<sub>n</sub> wherein W is as defined in claim 2 and n is 0-3 and n are as defined in claim 1, a pyrimidinyl group substituted by one or more substituents which are halogen or W<sub>n</sub> wherein a substituent selected from the group constituting of halogen and W<sub>n</sub>, whereas W is as defined in claim 2 and n is 0-3 and n are as defined in Claim 1, or a substituted pyridyl group substituted by one or more substituents which are halogen or W<sub>n</sub> a substituent selected from the group consisting of halogen and W<sub>n</sub> wherein W is as defined in claim 2 and n is 0-3 and n are as defined in claim 1.

7. (Currently Amended) A method of claim 91 6 wherein B of Formula I is a substituted phenyl group, a substituted pyrimidinyl group, or substituted pyrridyl group substituted 1 to 3 times by 1 or more substituents which are selected from the group consisting of -CN, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, -OH, up to per-halosubstituted ~~per halo-substituted~~ C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted ~~per halo-substituted~~ C<sub>1</sub>-C<sub>10</sub> alkoxy or phenyl substituted by halogen up to per-halosubstitution ~~per halo~~.

8. (Currently Amended) A method of claim 2 4, wherein L, the six member cyclic structure bound directly to D, is a substituted or unsubstituted 6 member aryl moiety or a substituted or unsubstituted 6 member hetaryl moiety, wherein said hetaryl moiety has 1 to 4 members which are selected from the group of heteroatoms consisting of nitrogen, oxygen or and sulfur with the balance of said hetaryl moiety being carbon, wherein the one or more substituents are selected from the group consisting of halogen or and W<sub>n</sub> W<sub>n</sub> wherein W is as defined in claim 2 and n is 0-3 and n are as defined in claim 1.

9. (Currently Amended) A method of claim 9 8, wherein L, the 6 member cyclic structure bound directly to D, is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group.

10. (Currently Amended) A method of claim 1, wherein said substituted cyclic moiety L<sup>1</sup> comprises pyridinyl a 5 to 6 membered aryl moiety or hetaryl moiety, wherein said heteraryl moiety comprises 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen or and sulfur.

11. (Currently Amended) A method of claim 2, wherein said substituted cyclic moiety L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

12. (Currently Amended) A method of claim 3, wherein said substituted cyclic moiety L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

13. (Currently Amended) A method of claim 6, wherein said substituted cyclic moiety L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

14. Cancelled

15. (Currently Amended) A method of claim 7, wherein said substituted cyclic moiety  $L^1$  is ~~phenyl, pyridinyl or pyrimidinyl~~.

16. Cancelled

17. (Currently Amended) A method of claim 8, wherein said substituted cyclic moiety  $L^1$  is ~~phenyl, pyridinyl or pyrimidinyl~~.

18. (Currently Amended) A method of claim 13, wherein M is one or more bridging groups which are selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen and R<sup>7</sup> is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing one or more heteroatoms which are N, S or O selected from N, S and O and optionally substituted by halogen up to per-halosubstitution per halo.

19. (Currently Amended) A method of claim 15, wherein M is one or more bridging groups which are selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen and R<sup>7</sup> is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing one or more heteroatoms which are N, S or O selected from N, S and O and optionally substituted by halogen up to per-halosubstitution per halo.

20. Cancelled

21. (Currently Amended) A method of claim 17, wherein M is one or more bridging groups ~~which are selected from the group consisting of~~ -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- ~~or and~~ -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen and R<sup>7</sup> is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing one or more heteroatoms which are N, S and O selected from N, S and O and optionally substituted by halogen up to per-halosubstitution per halo.

22. Cancelled

23. Cancelled

24. Cancelled

25. Cancelled

26. Cancelled

27. (Currently Amended) A method of claim 21 wherein L<sup>1</sup> is additionally substituted 1 to 3 times by one or more substituents ~~which are selected from the group consisting of~~ C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted per halo-substituted C<sub>1</sub>-C<sub>10</sub> alkyl, -CN, -OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per-halosubstituted per halo-substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

28. (Currently Amended) A method of claim 2 ~~±~~ wherein L<sup>1</sup> is substituted by -C(O)R<sub>x</sub>.

29. Cancelled

30. Cancelled

31. Cancelled

32. (Currently Amended) A method of claim 2 ~~±~~ wherein L<sup>1</sup> is pyridinyl substituted

by  $-C(O)R_x$  or  $-SO_2R_x$ , wherein  $R_x$  is  $NR_aR_b$ .

33. (Currently Amended) A method of claim 13 wherein  $L^1$  is pyridinyl substituted by  $-C(O)R_x$  or  $-SO_2R_x$ , wherein  $R_x$  is  $NR_aR_b$ , and  $R_a$  and  $R_b$  are

a) independently

i) hydrogen,

ii) a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms which are N, S or O selected from N, S and O and optionally substituted by halogen, hydroxy or a and carbon based substituent ~~substituents~~ of up to 24 carbon atoms[<sub>7</sub>] ~~which optionally contain~~ contains one or more heteroatoms which are N, S or O selected from N, S and O and is ~~are~~ optionally substituted by halogen, or

$-OSi(R_f)_3$  where  $R_f$  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms which are N, S or O selected from N, S and O and optionally substituted by halogen, hydroxy or a and carbon based substituent ~~substituents~~ of up to 24 carbon atoms[<sub>7</sub>] ~~which optionally contain~~ contains one or more heteroatoms which are N, S or O selected from N, S and O and is ~~are~~ optionally substituted by halogen; or

b)  $R_a$  and  $R_b$  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O selected from N, S and O substituted by halogen, hydroxy or a carbon based substituent ~~substituents~~ of up to 24 carbon atoms[<sub>7</sub>] ~~which optionally contain~~ contains one or more heteroatoms which are N, S or O selected from N, S and O and is ~~are~~ optionally substituted by halogen; or

c) one of  $R_a$  or  $R_b$  is  $-C(O)-$ , a  $C_1-C_5$  divalent alkylene group or a substituted  $C_1-C_5$  divalent alkylene group bound to the moiety  $L$  to form a cyclic structure with at least 5 members, wherein the substituent ~~substituents~~ of the substituted  $C_1-C_5$  divalent alkylene group are ~~selected from the group consisting of~~ halogen, hydroxy, or a and carbon based substituent

~~substituents of up to 24 carbon atoms[5] which optionally contain~~ contains one or more  
~~heteroatoms which are N, S and O selected from N, S and O and is~~ are optionally substituted by  
~~halogen.~~

34. Cancelled

35. Cancelled

36. Cancelled

37. (Currently Amended) A method of claim 21 wherein  $L^1$  is substituted by  $-C(O)R_x$  or  $-SO_2R_x$ , wherein  $R_x$  is  $NR_aR_b$  and  $R_a$  and  $R_b$  are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms which are N, S or O selected from N, S and O and optionally substituted by halogen, hydroxy or a and carbon based substituent ~~substituents of up to 24 carbon atoms [5] which optionally contain~~ contains one or more heteroatoms which are N, S or O selected from N, S and O and is ~~are~~ optionally substituted by halogen.

38. (Currently Amended) A method for the treatment of cancerous cell growth mediated by RAF kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound of Formula I:



or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is  $-NH-C(O)-NH-$ ,

A is ~~a substituted moiety of up to 40 carbon atoms~~ of the formula:  $-L-(M-L^1)_q$ , where L is a 6 membered aryl moiety or a 6 membered hetaryl moiety bound directly to D,  $L^1$  comprises a substituted cyclic moiety having at least 5 members, ~~M is a bridging group having at~~

~~least one atom; q is an integer of from 1-3; and each cyclic structure of L and L<sup>1</sup> contains 0-4 heteroatoms which are members of the group consisting of nitrogen, oxygen or and sulfur, and~~

~~B is a substituted or unsubstituted, phenyl, pyridyl or pyrimidinyl group up to trieyelic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,~~

~~wherein L<sup>1</sup> is substituted by at least one substituent which is selected from the group consisting of -SO<sub>2</sub>R<sub>x</sub>, -C(O)R<sub>x</sub> or and -C(NR<sub>y</sub>) R<sub>z</sub>,~~

~~R<sub>y</sub> is hydrogen or C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are O, N or S, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7-24</sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl, a carbon-based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,~~

~~R<sub>z</sub> is hydrogen or substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-12</sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-12</sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C<sub>3-12</sub> hetaryl up to per-halosubstituted heteroaryl, or a carbon-based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

~~R<sub>x</sub> is independently chosen from the R<sub>z</sub> moieties or is R<sub>z</sub> or NR<sub>a</sub>R<sub>b</sub> where R<sub>a</sub> and R<sub>b</sub> are~~

a) independently

i) hydrogen,

ii) C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are from N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl.

where R<sub>a</sub> or R<sub>b</sub> is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl, or a carbon-based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

iii) -OSi(R<sub>f</sub>)<sub>3</sub> where R<sub>f</sub> is hydrogen or a carbon-based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O,

substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where R<sub>f</sub> is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl,

or

b) R<sub>a</sub> and R<sub>b</sub> together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O selected from N, S and O substituted by halogen, or hydroxy or C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where the substituent on the 5-7 member heterocyclic structure is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl; or hydroxy or carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

c) one of  $R_a$  or  $R_b$  is  $-C(O)-$ , a  $C_1-C_5$  divalent alkylene group or a substituted  $C_1-C_5$  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted  $C_1-C_5$  divalent alkylene group are halogen, hydroxy  $C_1-C_{10}$  alkyl,  $C_1-C_{10}$  alkoxy,  $C_{3-10}$  cycloalkyl,  $C_{2-10}$  alkenyl,  $C_{1-10}$  alkenoyl,  $C_{6-12}$  aryl,  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O,  $C_{3-10}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $C_{7-24}$  aralkyl,  $C_{7-C_{24}}$  alkaryl, substituted  $C_{1-10}$  alkyl, substituted  $C_{1-10}$  alkoxy, substituted  $C_{3-10}$  cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted  $C_{6-12}$  aryl, substituted  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O, substituted  $C_{7-24}$  aralkyl, or substituted  $C_{7-24}$  alkaryl,

where the substituent on the  $C_1-C_5$  divalent alkylene is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy,  $C_{1-10}$  alkyl,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O,  $C_{1-10}$  alkoxy,  $C_{6-12}$  aryl,  $C_{1-6}$  halosubstituted alkyl up to per-halosubstituted alkyl,  $C_{6-C_{12}}$  halosubstituted aryl up to per-halosubstituted aryl,  $C_{3-C_{12}}$  halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted  $C_{3-C_{12}}$  hetaryl up to per-halosubstituted heteroaryl,

~~selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

where B is substituted, L is substituted or  $L^1$  is additionally substituted, the substituents are ~~selected from the group consisting of halogen, up to per-halosubstitution per-halo, and  $W_n$~~   $W_n$ , where n is 0-3;

wherein each W is ~~independently selected from the group consisting of~~  $-CN$ ,  $-CO_2R^7$ ,  $-C(O)NR^7R^7$ ,  $-C(O)-R^7$ ,  $-NO_2$ ,  $-OR^7$ ,  $-SR^7$ ,  $-NR^7R^7$ ,  $-NR^7C(O)OR^7$ ,  $-NR^7C(O)R^7$ ,  $-Q-Ar$ ,  $C_1-C_{10}$  alkyl,  $C_1-C_{10}$  alkoxy,  $C_{3-10}$  cycloalkyl,  $C_{2-10}$  alkenyl,  $C_{1-10}$  alkenoyl,  $C_{6-12}$  aryl,  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O,  $C_{3-10}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $C_{7-24}$  aralkyl,  $C_{7-C_{24}}$  alkaryl, substituted  $C_{1-10}$  alkyl, substituted  $C_{1-10}$  alkoxy,

substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

wherein W is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl,

~~and carbon-based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup> and halogen up to per-halo; with each R<sup>7</sup> independently selected from H or a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen;~~

wherein Q is -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, and X<sup>a</sup> is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are members selected from the group consisting of nitrogen, oxygen or and sulfur, which is optionally substituted by halogen, up to per-halosubstitution per-halo, and is optionally substituted by Z<sub>n1</sub>, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, C<sub>1-C<sub>10</sub></sub> alkyl, C<sub>1-C<sub>10</sub></sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl,

substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where Z is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl;

~~and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents are selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -COR<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, and -NR<sup>7</sup>C(O)OR<sup>7</sup>, with R<sup>7</sup> as defined above; and~~

~~wherein M is one or more bridging groups which are selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>-CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, and X<sup>a</sup> is halogen.~~

39. (Currently Amended) A method for the treatment of cancerous cell growth mediated by RAF kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound of Formula I:



or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is ~~a substituted moiety of up to 40 carbon atoms~~ of the formula: -L-(M-L<sup>1</sup>)<sub>q</sub>, where L is a substituted or unsubstituted phenyl pyridinyl moiety bound directly to D, L<sup>1</sup> comprises a substituted phenyl, pyridinyl or pyrimidinyl moiety, M is ~~a bridging group having at least one atom~~, q is an integer of from 1-3; and

B is a substituted or unsubstituted phenyl or ~~pyridinyl~~ pyridine group bound directly to D, wherein  $L^1$  is substituted by one or more substituents which are at least one substituent selected from the group consisting of  $-\text{SO}_2\text{R}_x$ ,  $-\text{C}(\text{O})\text{R}_x$  or and  $-\text{C}(\text{NR}_y)\text{R}_z$ ,

$\text{R}_y$  is hydrogen or  $\text{C}_1$ - $\text{C}_{10}$  alkyl,  $\text{C}_1$ - $\text{C}_{10}$  alkoxy,  $\text{C}_{3-10}$  cycloalkyl,  $\text{C}_{2-10}$  alkenyl,  $\text{C}_{1-10}$  alkenoyl,  $\text{C}_{6-12}$  aryl,  $\text{C}_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O,  $\text{C}_{3-10}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $\text{C}_{7-24}$  aralkyl,  $\text{C}_7$ - $\text{C}_{24}$  alkaryl, substituted  $\text{C}_{1-10}$  alkyl, substituted  $\text{C}_{1-10}$  alkoxy, substituted  $\text{C}_{3-10}$  cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted  $\text{C}_{6-12}$  aryl, substituted  $\text{C}_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O, substituted  $\text{C}_{7-24}$  aralkyl, or substituted  $\text{C}_{7-24}$  alkaryl,

where  $\text{R}_y$  is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy,  $\text{C}_{1-10}$  alkyl,  $\text{C}_{3-12}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $\text{C}_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O,  $\text{C}_{1-10}$  alkoxy,  $\text{C}_{6-12}$  aryl,  $\text{C}_{1-6}$  halosubstituted alkyl up to per-halosubstituted alkyl,  $\text{C}_6$ - $\text{C}_{12}$  halosubstituted aryl up to per-halosubstituted aryl,  $\text{C}_3$ - $\text{C}_{12}$  halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted  $\text{C}_3$ - $\text{C}_{12}$  hetaryl up to per-halosubstituted heteroaryl;

~~a carbon-based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo, and;~~

$\text{R}_z$  is hydrogen or  $\text{C}_1$ - $\text{C}_{10}$  alkyl,  $\text{C}_1$ - $\text{C}_{10}$  alkoxy,  $\text{C}_{3-10}$  cycloalkyl,  $\text{C}_{2-10}$  alkenyl,  $\text{C}_{1-10}$  alkenoyl,  $\text{C}_{6-12}$  aryl,  $\text{C}_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O,  $\text{C}_{3-10}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $\text{C}_{7-24}$  aralkyl,  $\text{C}_7$ - $\text{C}_{24}$  alkaryl, substituted  $\text{C}_{1-10}$  alkyl, substituted  $\text{C}_{1-10}$  alkoxy, substituted  $\text{C}_{3-10}$  cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted  $\text{C}_{6-12}$  aryl, substituted  $\text{C}_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O, substituted  $\text{C}_{7-24}$  aralkyl, or substituted  $\text{C}_{7-24}$  alkaryl,

where  $\text{R}_z$  is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy,  $\text{C}_{1-10}$  alkyl,  $\text{C}_{3-12}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $\text{C}_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O,  $\text{C}_{1-10}$  alkoxy,  $\text{C}_{6-12}$  aryl,  $\text{C}_{1-6}$  halosubstituted alkyl up to per-halosubstituted alkyl,  $\text{C}_6$ - $\text{C}_{12}$  halosubstituted aryl up to per-halosubstituted aryl,  $\text{C}_3$ - $\text{C}_{12}$

halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to per-halosubstituted heteroaryl,

~~a carbon-based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

R<sub>x</sub> is independently chosen from the R<sub>z</sub> moieties or is R<sub>z</sub> or NR<sub>a</sub>R<sub>b</sub> where R<sub>a</sub> and R<sub>b</sub> are

a) independently

i) hydrogen,

ii) C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7</sub>-C<sub>24</sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where R<sub>x</sub> is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6</sub>-C<sub>12</sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3</sub>-C<sub>12</sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to per-halosubstituted heteroaryl,

~~a carbon-based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or~~

iii) -OSi(R<sub>f</sub>)<sub>3</sub> where R<sub>f</sub> is hydrogen or C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are

N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where R<sub>f</sub> is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl, a carbon-based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

b) R<sub>a</sub> and R<sub>b</sub> together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O selected from N, S and O substituted by halogen, hydroxy or C<sub>1-C<sub>10</sub></sub> alkyl, C<sub>1-C<sub>10</sub></sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where the substituent on the 5-7 member heterocyclic structure is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3

heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to per-halosubstituted heteroaryl,

~~carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

c) one of R<sub>a</sub> or R<sub>b</sub> is -C(O)-, a C<sub>1</sub>-C<sub>5</sub> divalent alkylene group or a substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group are selected from the group consisting of halogen, hydroxy, and or a C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where the substituent on the C<sub>1</sub>-C<sub>5</sub> divalent alkylene is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to per-halosubstituted heteroaryl,

~~carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

where B is substituted, L is substituted or L<sup>1</sup> is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halosubstitution per-hale, or and W<sub>n</sub> W<sub>n</sub>, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -C(O)-R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -Q-Ar, or C<sub>1</sub>-

C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>7-24</sub> aralkyl, C<sub>7-24</sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where W is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6</sub>-C<sub>12</sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3</sub>-C<sub>12</sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to per-halosubstituted heteroaryl;

~~and carbon-based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup> and halogen up to per-halo; with each R<sup>7</sup> independently selected from H or a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,~~

wherein Q is -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, and X<sup>a</sup> is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are ~~members selected from the group consisting of~~ nitrogen, oxygen or and sulfur, which is optionally substituted by halogen, up to per-halosubstitution ~~per-halo~~, and optionally substituted by Z<sub>n1</sub>, wherein n1 is 0 to 3 and each Z is independently ~~selected from the group consisting of~~ -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>-NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub>

hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where Z is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl; and

~~and a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of CN, CO<sub>2</sub>R<sup>7</sup>, COR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7</sup>, OR<sup>7</sup>, SR<sup>7</sup>, NO<sub>2</sub>, NR<sup>7</sup>R<sup>7</sup>, NR<sup>7</sup>C(O)R<sup>7</sup>, and NR<sup>7</sup>C(O)OR<sup>7</sup>; and~~

wherein M is one or more bridging groups which are selected from the group consisting of -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>-CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, X<sup>a</sup> is halogen.

40. Cancelled

41. Cancelled

42. Cancelled

43. (Currently Amended) A method as in claim 38 wherein substituents for B and L and additional substituents for L<sup>1</sup>, ~~are selected from the group consisting of C<sub>1-C<sub>10</sub></sub> alkyl[<sub>1</sub>] up to per-halosubstituted per-halo-substituted C<sub>1-C<sub>10</sub></sub> alkyl, CN, OH, halogen, C<sub>1-C<sub>10</sub></sub> alkoxy or and up to per-halosubstituted per-halo substituted C<sub>1-C<sub>10</sub></sub> alkoxy.~~

45. (Currently Amended) A method as in claim 39 wherein substituents for B and L and additional substituents for L<sup>1</sup>, are ~~selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl[,] up to per-halosubstituted per-halo-substituted C<sub>1</sub>-C<sub>10</sub> alkyl, CN, OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy or and up to per-halosubstituted per-halo-substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.~~

46. (Previously Presented) A method of claim 38 wherein L<sup>1</sup> is pyridinyl substituted by C(O)R<sub>x</sub> or SO<sub>2</sub>R<sub>x</sub>.

47. (Previously Presented) A method of claim 39 wherein L<sup>1</sup> is pyridinyl substituted by C(O)R<sub>x</sub> or SO<sub>2</sub>R<sub>x</sub>.

48. (Currently Amended) A method of claim 46 wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>6</sub>-C<sub>12</sub>aryl, substituent substituted C<sub>1-10</sub> alkyl, substituents substituted C<sub>3-10</sub> cycloalkyl or substituted C<sub>6</sub>-C<sub>12</sub>aryl,

where R<sub>a</sub> or R<sub>b</sub> is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy or C<sub>1-10</sub> alkyl,

~~and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

49. (Currently Amended) A method of claim 47 wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3-10</sub> cycloalkyl or C<sub>6-12</sub> aryl.

~~and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based~~

substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

50. (Currently Amended) A method of claim 1 wherein the compound of Formula I ~~formula 1~~ is a pharmaceutically acceptable salt which is selected from the group consisting of

a) a basic salt salts of an organic acid acids or an and inorganic acid acids ~~which is selected from the group consisting of~~ hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or and mandelic acid; or and

b) an acid salt salts of an organic or and inorganic base bases containing a cation which is an alkali metal cation, an alkaline earth metal cation ~~eations selected from the group consisting of alkaline cations, alkaline earth eations,~~ the ammonium cation, an aliphatic substituted ammonium cation or an ~~eations~~ and aromatic substituted ammonium cation ~~eations~~.

51. Cancelled

52. (Currently Amended) A method of claim 33 wherein the compound of Formula I ~~formula 1~~ is a pharmaceutically acceptable salt which is selected from the group consisting of

a) a basic salt salts of an organic acid acids and-or an inorganic acid acids ~~which is selected from the group consisting of~~ hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or and

mandelic acid; or an and

b) an acid salt salts of an organic or and inorganic base bases containing a cation which is an alkali metal cation, an alkaline earth metal cation, eations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, an aliphatic substituted ammonium cation or an eations and aromatic substituted ammonium cation eations.

53. (Currently Amended) A method of claim 38 wherein the compound Formula I ~~formula 1~~ is a pharmaceutically acceptable salt which is selected from the group consisting of

a) a basic salt salts of an organic acid acids or an and inorganic acid acids selected from the group consisting of which is hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or and mandelic acid; or and

b) an acid salt salts of an organic or and inorganic base bases containing a cation which is an alkali metal cation, an alkaline earth metal cation eations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, an aliphatic substituted ammonium cation or an eations and aromatic substituted ammonium cation eations.

54. (Currently Amended) A method of claim 39 wherein the compound of Formula I ~~formula 1~~ is a pharmaceutically acceptable salt which is selected from the group consisting of

a) a basic salt salts of an organic acid acids or an and inorganic acid acids which is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid,

succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or ~~and~~ mandelic acid; or an ~~and~~

b) an acid salt salts of an organic or and inorganic base bases containing a cation which is an alkali metal cation, an alkaline earth metal cation ~~eations selected from the group consisting of alkaline eations, alkaline earth eations, the ammonium cation, an aliphatic substituted ammonium cation or an eations and aromatic substituted ammonium cation eations.~~

55. Cancelled

56. Cancelled

57. Cancelled

58. Cancelled

59. Cancelled

60. Cancelled

61. Cancelled

62. Cancelled

63. Cancelled

64. Cancelled

65. Cancelled

66. (Currently Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound which is a selected from the group consisting of

3-tert butyl phenyl urea ~~ureas of Table 1 above;~~

5-tert butyl-2-methoxyphenyl urea ~~ureas of Table 2 above;~~

5-(trifluoromethyl)-2 phenyl urea ~~ureas of Table 3 above;~~  
3-(trifluoromethyl) -4 chlorophenyl urea ~~ureas of Table 4 above;~~  
3-(trifluoromethyl)-4-bromophenyl urea ~~ureas of Table 5 above; or~~  
5-(trifluoromethyl)-4-chloro-2 methoxyphenyl urea ~~ureas of Table 6 above; and~~  
~~ureas 101-103 in Table 7 above.~~

67. (Currently Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound which is: selected from the group consisting of the one of the following 3-tert butyl phenyl ureas:

*N*-(3-*tert*-butylphenyl)-*N*'-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea or and  
*N*-(3-*tert*-butylphenyl)-*N*'-(4-(4-acetylphenoxy)phenyl) urea; or

one of the following ~~the~~ 5-*tert*-butyl-2-methoxyphenyl ureas:

*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N*'-(4-(1,3-dioxoisindolin-5-yl oxy)phenyl) urea,  
*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N*'-(4-(1-oxoisindolin-5-yl oxy)phenyl) urea,  
*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N*'-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea  
or and  
*N*-(5-*tert*-butyl-2-methoxyphenyl)-*N*'-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea; or

one of the following ~~the~~ 2-methoxy-5-trifluoromethyl)phenyl ureas:

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*'-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,  
*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*'-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,  
*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,  
*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea or and

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; or

one of the following the 4-chloro-3-(trifluoromethyl)phenyl ureas:

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,  
*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,  
*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea or and  
*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

or one of the following the 4-bromo 3-(trifluoromethyl)phenyl ureas:

*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,  
*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,  
*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,  
*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea or and  
*N*-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and

or one of the following the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea or and

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea, wherein said compound is administered in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

68. (Currently Amended) A method for the treatment of solid cancers in a human comprising administering to a human a compound of Formula I:



or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is ~~a substituted moiety of up to 40 carbon atoms~~ of the formula: -L-(M-L<sup>1</sup>)<sub>q</sub>, where L is a 5 or 6 membered cyclic structure bound directly to D, L<sup>1</sup> comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L<sup>1</sup> contains 0-4 heteroatoms which are members of the group consisting of nitrogen, oxygen or and sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 heteroatoms which are members of the group consisting of nitrogen, oxygen or and sulfur,

wherein L<sup>1</sup> is substituted by at least one substituent which is selected from the group

~~consisting of~~  $-\text{SO}_2\text{R}_x$ ,  $-\text{C}(\text{O})\text{R}_x$  or ~~and~~  $-\text{C}(\text{NR}_y)\text{R}_z$ ,

$\text{R}_y$  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally halosubstituted, up to per-halosubstitution per halo,

$\text{R}_z$  is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is optionally substituted by halogen, hydroxy or ~~and~~ a carbon based substituent ~~substituents~~ of up to 24 carbon atoms[,] which optionally ~~eontains~~ contain one or more heteroatoms which are N, S or O ~~selected from N, S and O~~ and is ~~are~~ optionally substituted by halogen;

$\text{R}_x$  is independently chosen from  $\text{R}_z$  moieties or is  $\text{R}_z$  ~~or~~  $\text{NR}_a\text{R}_b$  where  $\text{R}_a$  and  $\text{R}_b$  are

a) independently

i) hydrogen,

ii) a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms which are selected from N, S or O and optionally substituted by halogen, hydroxy or a and carbon based substituent substituents of up to 24 carbon atoms[5] which optionally contain contains one or more heteroatoms which are N, S or O selected from N, S and O and is are optionally substituted by halogen, or

iii). -OSi(R<sub>f</sub>)<sub>3</sub> where R<sub>f</sub> is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms which are N, S or O selected from N, S and O and optionally substituted by halogen, hydroxy or a and carbon based substituent substituents of up to 24 carbon atoms[5] which optionally contain contains one or more heteroatoms which are N, S or O selected from N, S and O and is are optionally substituted by halogen; or

b) R<sub>a</sub> and R<sub>b</sub> together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O selected from N, S and O substituted by halogen, hydroxy or a carbon based substituent substituents of up to 24 carbon atoms[5] which optionally contain contains one or more heteroatoms which are N, S or O selected from N, S and O and is are optionally substituted by halogen; or

c) one of R<sub>a</sub> or R<sub>b</sub> is -C(O)-, a C<sub>1</sub>-C<sub>5</sub> divalent alkylene group or a substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group are selected from the group consisting of halogen, hydroxy, or a and carbon based substituent substituents of up to 24 carbon atoms[5] which optionally contain contains one or more heteroatoms which are N, S or O selected from N, S and O and is are optionally substituted by halogen;

where B is substituted, L is substituted or L<sup>1</sup> is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo or -, and W<sub>n</sub> W<sub>n</sub>, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -C(O)-R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -Q-Ar, or a and carbon based moiety moieties of up to 24 carbon atoms, optionally containing one or more

heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by one or more substituents which are independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup> or and halogen up to per-halosubstitution per-hale; with each R<sup>7</sup> independently selected from H or a carbon based moiety of up to 24 carbon atoms[7] optionally containing heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, and X<sup>a</sup> is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are members ~~selected from the group consisting of~~ nitrogen, oxygen or and sulfur, which is optionally substituted by halogen, up to per-halosubstitution per-hale, and optionally substituted by Zn<sub>n1</sub>, wherein n1 is 0 to 3 and each Z is independently ~~selected from the group consisting of~~ -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, or and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms which are N, S or O ~~selected from N, S and O~~ and optionally substituted by one or more substituents which are ~~selected from the group consisting of~~ -CN, -CO<sub>2</sub>R<sup>7</sup>, -COR<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, or and -NR<sup>7</sup>C(O)OR<sup>7</sup>, with R<sup>7</sup> as defined above.

69. (Currently amended) A method for the treatment of carcinomas, myleoid disorders or adenomas in a human comprising administering to a human a compound of Formula I:



or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is ~~a substituted moiety of up to 40 carbon atoms~~ of the formula: -L-(M-L<sup>1</sup>)<sub>q</sub>, where L

is a 5 or 6 membered cyclic structure bound directly to D,  $L^1$  comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and  $L^1$  contains 0-4 members heteroatoms which are of the group consisting of nitrogen, oxygen or and sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 heteroatoms which are members of the group consisting of nitrogen, oxygen or and sulfur,

wherein  $L^1$  is substituted by at least one or more substituents substituent which are selected from the group consisting of  $-SO_2R_x$ ,  $-C(O)R_x$  or and  $-C(NR_y)R_z$ ,

$R_y$  is hydrogen or  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  alkoxy,  $C_{3-10}$  cycloalkyl,  $C_{2-10}$  alkenyl,  $C_{1-10}$  alkenoyl,  $C_{6-12}$  aryl,  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O,  $C_{3-10}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $C_{7-24}$  aralkyl,  $C_7$ - $C_{24}$  alkaryl, substituted  $C_{1-10}$  alkyl, substituted  $C_{1-10}$  alkoxy, substituted  $C_{3-10}$  cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted  $C_{6-12}$  aryl, substituted  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O, substituted  $C_{7-24}$  aralkyl, or substituted  $C_{7-24}$  alkaryl,

where  $R_y$  is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy,  $C_{1-10}$  alkyl,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S and O,  $C_{1-10}$  alkoxy,  $C_{6-12}$  aryl,  $C_{1-6}$  halosubstituted alkyl up to per-halosubstituted alkyl,  $C_6$ - $C_{12}$  halosubstituted aryl up to per-halosubstituted aryl,  $C_3$ - $C_{12}$  halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted  $C_3$ - $C_{12}$  hetaryl up to per-halosubstituted heteroaryl, or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,

$R_z$  is hydrogen  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  alkoxy,  $C_{3-10}$  cycloalkyl,  $C_{2-10}$  alkenyl,  $C_{1-10}$  alkenoyl,  $C_{6-12}$  aryl,  $C_{3-12}$  hetaryl having 1-3 heteroatoms which are N, S or O,  $C_{3-10}$  cycloalkyl having 0-3 heteroatoms which are N, S or O,  $C_{7-24}$  aralkyl,  $C_7$ - $C_{24}$  alkaryl, substituted  $C_{1-10}$  alkyl, substituted  $C_{1-10}$  alkoxy, substituted  $C_{3-10}$  cycloalkyl, having 0-3 heteroatoms which are N, S or

O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where R<sub>z</sub> is substituted it is substituted by halogen up to per-halosubstituted, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl, or a carbon-based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R<sub>x</sub> is independently chosen from R<sub>z</sub> moieties or is R<sub>z</sub> or NR<sub>a</sub>R<sub>b</sub> where R<sub>a</sub> and R<sub>b</sub> are

a) independently

i.) hydrogen,

ii.) C<sub>1-C<sub>10</sub></sub> alkyl, C<sub>1-C<sub>10</sub></sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where R<sub>x</sub> is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl,

~~a carbon-based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

iii.) -OSi(R<sub>f</sub>)<sub>3</sub> where R<sub>f</sub> is hydrogen C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

wherein R<sub>f</sub> is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl,  
~~or a carbon-based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

or

b) R<sub>a</sub> and R<sub>b</sub> together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S, or O selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O selected from N, S and O substituted by halogen, hydroxy a C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl,

substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where the substituent on the 5-7 member heterocyclic structure is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3-C<sub>12</sub></sub> hetaryl up to per-halosubstituted heteroaryl, carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

c) one of R<sub>a</sub> or R<sub>b</sub> is -C(O)-, a C<sub>1</sub>-C<sub>5</sub> divalent alkylene group or a substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group are selected from the group consisting of halogen, hydroxy, or a ~~and~~ C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>7-24</sub> aralkyl, C<sub>7-C<sub>24</sub></sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where the substituents on the C<sub>1-5</sub> divalent alkylene group is substituted, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C<sub>12</sub></sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C<sub>12</sub></sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3-C<sub>12</sub></sub>

~~hetaryl up to per-halosubstituted heteroaryl, carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

where B is substituted, L is substituted or L<sup>1</sup> is additionally substituted, the substituents are ~~selected from the group consisting of halogen, up to per-halosubstitution per-halo, and W<sub>n</sub> W<sub>n</sub>~~, where n is 0-3;

wherein each W is independently ~~selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -C(O)-R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -Q-Ar, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>7-24</sub> aralkyl, C<sub>7-24</sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl.~~

~~where W is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6</sub>-C<sub>12</sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3</sub>-C<sub>12</sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to per-halosubstituted heteroaryl, selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -C(O)-R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -Q-Ar, and carbon-based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup> and halogen up to per-halo; with each R<sup>7</sup> independently selected from H or a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally~~

substituted by halogen,

wherein Q is -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>- CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- and -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, or and X<sup>a</sup> is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are members selected from the group consisting of nitrogen, oxygen or and sulfur, which is optionally substituted by halogen, up to per-halosubstitution per-halo, and optionally substituted by Z<sub>n1</sub>, wherein n1 is 0 to 3 and each Z is independently ~~selected from the group consisting of~~ -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup> -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, or C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>3-10</sub> cycloalkyl having 0-3 heteroatoms which are N, S and O, C<sub>7-24</sub> aralkyl, C<sub>7</sub>-C<sub>24</sub> alkaryl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>3-10</sub> cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C<sub>6-12</sub> aryl, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, substituted C<sub>7-24</sub> aralkyl, or substituted C<sub>7-24</sub> alkaryl,

where Ar is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms selected from O, S and N, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6</sub>-C<sub>12</sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3</sub>-C<sub>12</sub> halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S and O, up to per-halosubstituted cycloalkyl, or halosubstituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to per-halosubstituted heteroaryl,

~~and a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of CN, CO<sub>2</sub>R<sup>7</sup>, COR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7</sup>, OR<sup>7</sup>, SR<sup>7</sup>, NO<sub>2</sub>, NR<sup>7</sup>R<sup>7</sup>, NR<sup>7</sup>C(O)R<sup>7</sup>, and NR<sup>7</sup>C(O)OR<sup>7</sup>, with R<sup>7</sup> as defined above.~~

70. (Previously Presented) A method as in claim 38 for the treatment of carcinomas, myleoid disorders or adenomas.

71. (Previously Presented) A method as in claim 39 for the treatment of carcinomas, myleoid disorders or adenomas.

72. (Previously Presented) A method as in claim 50 for the treatment of carcinomas, myleoid disorders or adenomas.

73. (Previously Presented) A method as in claim 67 for the treatment of carcinomas, myleoid disorders or adenomas.

74. (Previously Presented) A method as in claim 1 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon mediated by RAF kinase.

75. (Previously Presented) A method as in claim 38 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

76. (Previously Presented) A method as in claim 39 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

77. (Previously Presented) A method as in claim 50 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

78. (Previously Presented) A method as in claim 67 for the treatment of carcinoma of

the lung, pancreas, thyroid, bladder or colon.

79. (Previously Presented) A method as in claim 1 for the treatment of myeloid leukemia or villous colon adenomas mediated by RAF kinase.

80. (Previously Presented) A method as in claim 28 for the treatment of myeloid leukemia or villous colon adenomas.

81. (Previously Presented) A method as in claim 39 for the treatment of myeloid leukemia or villous colon adenomas.

82. (Previously Presented) A method as in claim 50 for the treatment of myeloid leukemia or villous colon adenomas.

83. (Previously Presented) A method as in claim 67 for the treatment of myeloid leukemia or villous colon adenomas.

Please add the following claims:

--84. (New) A method as in claim 1 wherein said composition of Formula I is administered in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

85. (New) A method as in claim 3 wherein:

$R_y$ ,  $R_z$ ,  $R_a$ , and  $R^7$  are each independently hydrogen,  $C_{1-10}$  alkyl optionally

substituted by halogen up to per-halosubstitution or C<sub>1-10</sub> alkoxy optionally substituted by halogen up to per-halosubstitution.

86. (New) A method as in claim 85 wherein said substituted cyclic moiety L<sup>1</sup> is pyridinyl.

87. (New) A method of claim 8 wherein L<sup>1</sup> is pyridyl substituted by C(O)R<sub>x</sub> wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently hydrogen or C<sub>1</sub>-C<sub>10</sub> alkyl.

88. (New) A method for the treatment of cancerous cell growth in a human or other mammal comprising administering to a human or other mammal in need thereof:

*N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,  
*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea

in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

89. (New) A method for the treatment of cancerous cell growth mediated by raf kinase in a human or other mammal comprising administering to a human or other mammal in need thereof:

*N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea

in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

90. (New) A method for the treatment of a raf mediated disorder in a human or other mammal which comprises administering to a human or other mammal in need thereof;

*N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea

in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

91. (New) A method for treatment of a raf mediated disorder in a human or other mammal, comprising administering to a human or other mammal in need thereof a pharmaceutical composition comprising a compound of Formula I:



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of the formula:



wherein L is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl up to per-halosubstituted, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> haloalkoxy up to per-halosubstituted alkoxy, hydroxy, amino, C<sub>1</sub>-C<sub>3</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> dialkylamino, halogen, cyano or nitro;

(ii) a 5 membered monocyclic heteroaryl group, having 1-2 heteroatoms which are, independently, N, S or O, optionally substituted with 1-3 substituents which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl up to per-halosubstitution, C<sub>1</sub>-C<sub>3</sub> haloalkoxy up to per-halosubstituted alkoxy, hydroxy, amino, C<sub>1</sub>-C<sub>3</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> dialkylamino, halogen, cyano, or nitro; or

(iii) a 6 membered monocyclic heteroaryl group having 1-4 heteroatoms which are, independently, N, S or O, optionally substituted with 1-3 substituents, which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl up to per-halosubstitution, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> haloalkoxy up to per-halosubstituted alkoxy, hydroxy, amino, C<sub>1</sub>-C<sub>3</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> dialkylamino, halogen, cyano or nitro;

L<sup>1</sup> comprises a substitution cyclic moiety which is

(i) phenyl, optionally substituted with 1-3 substituents which are independently, R<sup>7</sup>, OR<sup>7</sup>,

$\text{NR}^7\text{R}^7$ ,  $\text{C(O)R}^7$ ,  $\text{C(O)OR}^7$ ,  $\text{C(O)NR}^7\text{R}^7$ ,  $\text{NR}^7\text{C(O)R}^7$ ,  $\text{NR}^7\text{C(O)OR}^7$ , halogen, cyano or nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents which are, independently,  $\text{R}^7$ ,  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^7$ ,  $\text{C(O)R}^7$ ,  $\text{C(O)OR}^7$ ,  $\text{C(O)NR}^7\text{R}^7$ ,  $\text{NR}^7\text{C(O)R}^7$ ,  $\text{NR}^7\text{C(O)OR}^7$ , halogen, cyano or nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-4 heteroatoms which are independently N, S or O, optionally substituted with 1-3 substituents which are independently  $\text{R}^7$ ,  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^7$ ,  $\text{C(O)R}^7$ ,  $\text{C(O)OR}^7$ ,  $\text{C(O)NR}^7\text{R}^7$ ,  $\text{NR}^7\text{C(O)R}^7$ ,  $\text{NR}^7\text{C(O)OR}^7$ , halogen, cyano or nitro;

(iv) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms which are independently, N, S or O, optionally substituted with 1-3 substituents which are independently,  $\text{R}^7$ ,  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^7$ ,  $\text{C(O)R}^7$ ,  $\text{C(O)OR}^7$ ,  $\text{C(O)NR}^7\text{R}^7$ ,  $\text{NR}^7\text{C(O)R}^7$ ,  $\text{NR}^7\text{C(O)OR}^7$ , halogen, cyano or nitro;

(v) saturated and partially saturated  $\text{C}_3\text{-C}_6$  monocyclic carbocyclic moieties optionally substituted with 1-3 substituents which are independently,  $\text{R}^7$ ,  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^7$ ,  $\text{C(O)R}^7$ ,  $\text{C(O)OR}^7$ ,  $\text{C(O)NR}^7\text{R}^7$ ,  $\text{NR}^7\text{C(O)R}^7$ ,  $\text{NR}^7\text{C(O)OR}^7$ , halogen, cyano or nitro;

(vi) saturated and partially saturated  $\text{C}_8\text{-C}_{10}$  bicyclic carbocyclic moieties, optionally substituted with 1-3 substituents which are independently,  $\text{R}^7$ ,  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^7$ ,  $\text{C(O)R}^7$ ,  $\text{C(O)OR}^7$ ,  $\text{C(O)NR}^7\text{R}^7$ ,  $\text{NR}^7\text{C(O)R}^7$ ,  $\text{NR}^7\text{C(O)OR}^7$ , halogen, cyano or nitro;

(vii) saturated and partially saturated 5 and 6 membered monocyclic heterocyclic moieties, having 1-3 heteroatoms which are independently, N, S or O, optionally substituted with 1-3 substituents which are independently,  $\text{R}^7$ ,  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^7$ ,  $\text{C(O)R}^7$ ,  $\text{C(O)OR}^7$ ,  $\text{C(O)NR}^7\text{R}^7$ ,  $\text{NR}^7\text{C(O)R}^7$ ,  $\text{NR}^7\text{C(O)OR}^7$ , halogen, cyano or nitro; or

(viii) saturated and partially saturated 8 to 10 membered bicyclic heterocyclic moieties, having 1-6 heteroatoms which are independently, N, S or O, optionally substituted with 1-3 substituents which are independently,  $\text{R}^7$ ,  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^7$ ,  $\text{C(O)R}^7$ ,  $\text{C(O)OR}^7$ ,  $\text{C(O)NR}^7\text{R}^7$ ,  $\text{NR}^7\text{C(O)R}^7$ ,  $\text{NR}^7\text{C(O)OR}^7$ , halogen, cyano or nitro;

wherein  $\text{L}^1$  is substituted by one or more substituents which are  $-\text{SO}_2\text{R}_x$ ,  $-\text{C(O)R}_x$  or

-C(NR<sub>y</sub>) R<sub>z</sub>,

wherein R<sub>z</sub> is

a) independently hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl having 0-3 which are N, S or O heteroatoms, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-C12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>7-24</sub> alkaryl, C<sub>7-24</sub> aralkyl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>6-C14</sub> aryl, substituted C<sub>3-C10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> alkaryl or substituted C<sub>7-C24</sub> aralkyl

where R<sub>z</sub> is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms selected from N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl up to per-halosubstituted alkyl, C<sub>6-C12</sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3-C12</sub> halosubstituted cycloalkyl up to per-halosubstituted per-halo cycloalkyl having 0-3 heteroatoms which are N, S or O, halosubstituted C<sub>3-C12</sub> hetaryl up to per-halosubstituted hetaryl having 1-3 heteroatoms which are N, S or O, halosubstituted C<sub>7-C24</sub> aralkyl up to per-halosubstituted aralkyl, or halosubstituted C<sub>7-C24</sub> alkaryl up to per-halosubstituted alkaryl,

wherein R<sub>x</sub> is independently chosen from R<sub>z</sub> moieties or is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are

a) independently hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, C<sub>3-10</sub> cycloalkyl having 0-3 which are N, S or O heteroatoms, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub> alkenoyl, C<sub>6-12</sub> aryl, C<sub>3-C12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, C<sub>7-24</sub> alkaryl, C<sub>7-24</sub> aralkyl, substituted C<sub>1-10</sub> alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>6-C14</sub> aryl, substituted C<sub>3-C10</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, substituted C<sub>3-12</sub> hetaryl having 1-3 heteroatoms which are N, S or O, substituted C<sub>7-24</sub> alkaryl or substituted C<sub>7-C24</sub> aralkyl,

where R<sub>a</sub> or R<sub>b</sub> is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl having 0-3 heteroatoms which are N, S or O, C<sub>3-12</sub> hetaryl having 1-3 heteroatoms selected from N, S and O, C<sub>1-10</sub> alkoxy, C<sub>6-12</sub> aryl, C<sub>1-6</sub> halosubstituted alkyl

up to per-halosubstituted alkyl, C<sub>6</sub>-C<sub>12</sub> halosubstituted aryl up to per-halosubstituted aryl, C<sub>3</sub>-C<sub>12</sub> halosubstituted cycloalkyl up to per-halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, halosubstituted C<sub>3</sub>-C<sub>12</sub> hetaryl up to per-halosubstituted hetaryl having 1-3 heteroatoms which are N, S or O, halosubstituted C<sub>7</sub>-C<sub>24</sub> aralkyl up to per-halosubstituted aralkyl, or halosubstituted C<sub>7</sub>-C<sub>24</sub> alkaryl up to per-halosubstituted alkaryl, or

b) combined together to form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O, optionally substituted by halogen hydroxy or C<sub>1-10</sub> alkyl; or

c) one of R<sub>a</sub> or R<sub>b</sub> is -C(O)-, a C<sub>1</sub>-C<sub>5</sub> divalent alkylene group or a substituted C<sub>1</sub>-C<sub>5</sub> divalent alkylene group bound to the moiety L<sup>1</sup> to form a cyclic structure with at least 5 members, wherein the substituents of the substituted

C<sub>1</sub>-C<sub>5</sub> divalent alkylene group are halogen hydroxy, or C<sub>1-10</sub> alkyl;

wherein M is one or more bridging groups which are -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>-, -CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where m= 1-3, and X<sup>a</sup> is halogen and

B is:

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7</sup>, NR<sup>7</sup>C(O)R<sup>7</sup>, NR<sup>7</sup>C(O)OR<sup>7</sup>, halogen, cyano, or nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7</sup>, NR<sup>7</sup>C(O)R<sup>7</sup>, NR<sup>7</sup>C(O)OR<sup>7</sup>, halogen, cyano, or nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-4 heteroatoms which are, independently, O, N or S, optionally substituted with 1-3 substituents which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7</sup>, NR<sup>7</sup>C(O)R<sup>7</sup>, NR<sup>7</sup>C(O)OR<sup>7</sup>, halogen, cyano, or nitro; or

(iv) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms which are, independently, N, S or O, optionally substituted with 1-3 substituents which are, independently,  $R^7$ ,  $OR^7$ ,  $NR^7R^{7'}$ ,  $C(O)R^7$ ,  $C(O)OR^7$ ,  $C(O)NR^7R^{7'}$ ,  $NR^7C(O)R^7$ ,  $NR^7C(O)OR^7$ , halogen, cyano, or nitro;

each  $R_y$  is independently

(a) hydrogen,

(b)  $C_1-C_6$  alkyl, optionally substituted with halogen up to per-halosubstitution,

(c)  $C_1-C_6$  alkoxy, optionally substituted with 1-3 halogen substituents,

(d)  $C_3-C_6$  cyclic alkyl, optionally substituted with 1-3 halogen substituents,

(e) phenyl, optionally substituted with 1-3 halogen substituents,

(f) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 halogen substituents, or

(g)  $C_1-C_3$  alkyl-phenyl, optionally substituted with 1-3 halogen substituents,

each  $R^7$  and  $R^{7'}$ , is independently

(a) hydrogen,

(b)  $C_1-C_6$  alkyl, optionally substituted with 1-3 substituents which are, independently,  $C_1-C_5$  alkyl, up to per-halosubstituted  $C_1-C_5$  alkyl,  $C_1-C_3$  alkoxy or hydroxy ;

(c)  $C_1-C_6$  alkoxy, optionally substituted with 1-3 substituents which are, independently,  $C_1-C_5$ , up to per-halosubstituted  $C_1-C_5$  alkyl,  $C_1-C_3$  alkoxy, hydroxy or halogen;

(d) phenyl, optionally substituted with 1-3 substituents which are, independently,  $C_1-C_5$  alkyl, up to per-halosubstituted  $C_1-C_5$  alkyl,  $C_1-C_3$  alkoxy, hydroxy or halogen,

(e) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 substituents which are, independently,  $C_1-C_5$  alkyl, up to per-halosubstituted

C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy or halogen,

(f) C<sub>1</sub>-C<sub>3</sub> alkyl-phenyl, optionally substituted with 1-3 substituents which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, up to per-halosubstituted C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy or halogen; and

(g) up to per-halosubstituted C<sub>1</sub>-C<sub>5</sub>, and where not per-halosubstituted, optionally substituted with 1-3 substituents which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, up to per-halosubstituted C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or hydroxy.

92. (New) A method as in claim 91 wherein M is one or more bridging groups is -O-, -S-, -N(R<sup>7</sup>)-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)O-, -(CH<sub>2</sub>)S-, -(CH<sub>2</sub>)N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)-, -CHF-, -CF<sub>2</sub>-, -S-(CH<sub>2</sub>)- and -N(R<sup>7</sup>)(CH<sub>2</sub>)-, -C(O)CH<sub>2</sub>-, -CH<sub>2</sub>OC(O)-, -C(O)OCH<sub>2</sub>-, -C(O)N(R<sup>7</sup>)CH<sub>2</sub>-, -N(R<sup>7</sup>)C(O)CH<sub>2</sub>-, or -N(R<sup>7</sup>)C(O)OCH<sub>2</sub>-, where R<sup>7</sup> is as defined in claim 91.

93. (New) A method as in claim 91 wherein B of Formula I is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7'</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7'</sup>, NR<sup>7</sup>C(O)R<sup>7'</sup>, NR<sup>7</sup>C(O)OR<sup>7'</sup>, halogen, cyano, or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7'</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7'</sup>, NR<sup>7</sup>C(O)R<sup>7'</sup>, NR<sup>7</sup>C(O)OR<sup>7'</sup>, halogen, cyano, or nitro; or

(iii) pyrimidinyl, optionally substituted with 1-3 substituents which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7'</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7'</sup>, NR<sup>7</sup>C(O)R<sup>7'</sup>, NR<sup>7</sup>C(O)OR<sup>7'</sup>, halogen, cyano, or nitro.

94. (New) A method as in claim 91 wherein B of Formula I is phenyl, or pyridinyl 1,

substituted 1 to 3 times by one or more substituents which are independently -CN, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -OH, up to per-halosubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, up to per halosubstituted C<sub>1</sub>-C<sub>6</sub> alkoxy or phenyl substituted by halogen up to per-halosubstitution.

95. (New) A method as in claim 94, wherein L is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7'</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7'</sup>, NR<sup>7</sup>C(O)R<sup>7'</sup>, NR<sup>7</sup>C(O)OR<sup>7'</sup>, halogen, cyano or nitro;  
or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, R<sup>1</sup>, OR<sup>1</sup>, NR<sup>1</sup>R<sup>2</sup>, C(O)R<sup>1</sup>, C(O)OR<sup>1</sup>, C(O)NR<sup>1</sup>R<sup>2</sup>, NR<sup>1</sup>C(O)R<sup>2</sup>, NR<sup>1</sup>C(O)OR<sup>2</sup>, halogen, cyano, or nitro.

96. (New) A method as in claim 91, wherein L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

97. (New) A method as in claim 93 wherein L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

98. (New) A method as in claim 94, wherein L<sup>1</sup> is phenyl or pyridinyl.

99. (New) A method as in claim 95, wherein L<sup>1</sup> is phenyl or pyridinyl.

100. (New) A method as in claim 97, wherein M is -O-, -S-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)O-, -(CH<sub>2</sub>)S-, -O(CH<sub>2</sub>)-, -S-(CH<sub>2</sub>)-, -CHF-, -CF<sub>2</sub>- or -C(O)CH<sub>2</sub>-.

101. (New) A method as in claim 98, wherein M is -O-, -S-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)O-, -(CH<sub>2</sub>)S-, -O(CH<sub>2</sub>)-, -CHF-, -CF<sub>2</sub>-, -S-(CH<sub>2</sub>)- or -C(O)CH<sub>2</sub>-.

102. (New) A method as in claim 99, wherein M is -O-, -S-, -(CH<sub>2</sub>)O-, -(CH<sub>2</sub>)S-, -O(CH<sub>2</sub>)-, -CHF-, -CF<sub>2</sub>-, -S-(CH<sub>2</sub>)- or -C(O)CH<sub>2</sub>-.

103. (New) A method as in claim 91 wherein L<sup>1</sup> is substituted by -C(O)R<sub>x</sub>.

104. (New) A method of claim 100 wherein L<sup>1</sup> is substituted by -C(O)R<sub>x</sub> wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub>.

105. (New) A method as in claim 101 wherein L<sup>1</sup> is substituted by -C(O)R<sub>x</sub>, wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> alkoxy.

106. (New) A method as in compound of claim 102 wherein L<sup>1</sup> is substituted by -C(O)R<sub>x</sub>, wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> alkoxy.


107. (New) A method for the treatment of a raf mediated disorder in a human or other mammal, comprising administering to a human or other mammal in need thereof, a pharmaceutical composition comprising a compound of Formula I:



or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is of the formula:



where L is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl up to per-halosubstituted alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy, amino, C<sub>1</sub>-

C<sub>3</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> dialkylamino, halogen, cyano, or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl up to per-halosubstituted alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy, amino, C<sub>1</sub>-C<sub>3</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> dialkylamino, halogen, cyano, or nitro; and

M is one or more bridging groups which are -O-, -S-, -N(R<sup>7</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>7</sup>)-, -O(CH<sub>2</sub>)<sub>m</sub>-CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or -N(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>-, where each m is independently an integer of from 1-3, X<sup>a</sup> is halogen, and

L<sup>1</sup> comprises a substituted cyclic moiety which is:

(i) naphthyl, optionally substituted with 1-3 substituents which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7'</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7'</sup>, NR<sup>7</sup>C(O)R<sup>7'</sup>, NR<sup>7</sup>C(O)OR<sup>7'</sup>, halogen, cyano or nitro;

(ii) 5 and 6 membered monocyclic heteroaryl groups, having 1-4 heteroatoms which are, independently, N, S or O, optionally substituted with 1-3 substituents which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7'</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7'</sup>, NR<sup>7</sup>C(O)R<sup>7'</sup>, NR<sup>7</sup>C(O)OR<sup>7'</sup>, halogen, cyano or nitro;

(iii) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms, which are, independently, N, S or O, optionally substituted with 1-3 substituents, which are, independently, R<sup>7</sup>, OR<sup>7</sup>, NR<sup>7</sup>R<sup>7'</sup>, C(O)R<sup>7</sup>, C(O)OR<sup>7</sup>, C(O)NR<sup>7</sup>R<sup>7'</sup>, NR<sup>7</sup>C(O)R<sup>7'</sup>, NR<sup>7</sup>C(O)OR<sup>7'</sup>, halogen, cyano or nitro;

wherein L<sup>1</sup> is substituted by one or more substituents which are -SO<sub>2</sub>R<sub>x</sub>, -C(O)R<sub>x</sub> or -C(NR<sub>y</sub>)R<sub>z</sub>,

wherein R<sub>x</sub> independently chosen from the moieties of R<sub>z</sub> or NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently chosen from the moieties of R<sub>z</sub>;

and

B is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently,  $R^7$ ,  $OR^7$ ,  $NR^7R^{7'}$ ,  $C(O)R^7$ ,  $C(O)OR^7$ ,  $C(O)NR^7R^{7'}$ ,  $NR^7C(O)R^{7'}$ ,  $NR^7C(O)OR^{7'}$ , halogen, cyano, or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently,  $R^7$ ,  $OR^7$ ,  $NR^7R^{7'}$ ,  $C(O)R^7$ ,  $C(O)OR^7$ ,  $C(O)NR^7R^{7'}$ ,  $NR^7C(O)R^{7'}$ ,  $NR^7C(O)OR^{7'}$ , halogen, cyano, or nitro;

each  $R_y$  is independently

(a) hydrogen,

(b)  $C_1$ - $C_6$  alkyl, optionally substituted with halogen up to per-halosubstitution,

(c)  $C_1$ - $C_6$  alkoxy, optionally substituted with 1-3 halogen substituents,

(d)  $C_3$ - $C_6$  cyclic alkyl, optionally substituted with 1-3 halogen substituents,

(e) phenyl, optionally substituted with 1-3 halogen substituents,

(f) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 halogen substituents, or

(g)  $C_1$ - $C_3$  alkyl-phenyl, optionally substituted with 1-3 halogen substituents,

each  $R^7$ ,  $R^{7'}$  and  $R_z$  is independently

(a) hydrogen,

(b)  $C_1$ - $C_6$  optionally substituted with 1-3 substituents which are, independently,  $C_1$ - $C_5$  alkyl, up to per-halosubstituted  $C_1$ - $C_5$  alkyl,  $C_1$ - $C_3$  alkoxy or hydroxy ;

(c)  $C_1$ - $C_6$  alkoxy, optionally substituted with 1-3 substituents which are, independently,  $C_1$ - $C_5$  alkyl, up to per-halosubstituted  $C_1$ - $C_5$  alkyl,  $C_1$ - $C_3$  alkoxy, hydroxy or halogen;

(d) phenyl, optionally substituted with 1-3 substituents which are, independently,  $C_1$ - $C_5$  alkyl, up to per-halosubstituted  $C_1$ - $C_5$  alkyl,  $C_1$ - $C_3$  alkoxy, hydroxy or halogen,

(e) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 substituents which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, up to per-halosubstituted C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy or halogen,

(f) C<sub>1</sub>-C<sub>3</sub> alkyl-phenyl, optionally substituted with 1-3 substituents, which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, up to per-halosubstituted C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, hydroxy or halogen; or

(g) up to per-halosubstituted C<sub>1</sub>-C<sub>5</sub> alkyl, and where not per-halosubstituted, optionally substituted with 1-3 substituents which are, independently, C<sub>1</sub>-C<sub>5</sub> alkyl, up to per-halosubstituted C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or hydroxy.

108. (New) A method as in claim 107 wherein substituents for B and L and additional substituents for L<sup>1</sup>, one C<sub>1</sub>-C<sub>6</sub> alkyl up to per-halosubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, CN, OH, halogen, C<sub>1</sub>-C<sub>6</sub> alkoxy or up to per-halosubstituted C<sub>1</sub>-C<sub>6</sub> alkoxy.

109. (New) A method of claim 107 wherein L<sup>1</sup> is pyridyl and is substituted by C(O)R<sub>x</sub> or SO<sub>2</sub> NR<sub>a</sub>R<sub>b</sub>.

110. (New) A method of claim 91 wherein a pharmaceutically acceptable salt of a compound of Formula I of claim 91 is used which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid,

lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

111. (New) A method of claim 107 wherein a pharmaceutically acceptable salt of a compound Formula I of claim 61 which is selected from the group consisting of

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

112. (New) A method of claim 91 wherein the substituted or unsubstituted monocyclic heteroaryl groups of B, L and L<sup>1</sup> are, independently,

2- and 3-furyl,

2- and 3-thienyl,

2- and 4-triazinyl,

1-, 2- and 3-pyrrolyl,

1-, 2-, 4- and 5-imidazolyl,  
1-, 3-, 4- and 5-pyrazolyl,  
2-, 4- and 5-oxazolyl,  
3-, 4- and 5-isoxazolyl,  
2-, 4- and 5-thiazolyl,  
3-, 4- and 5-isothiazolyl,  
2-, 3- and 4-pyridyl,  
2-, 4-, 5- and 6-pyrimidinyl,  
1,2,3-triazol-1-, -4- and -5-yl,  
1,2,4-triazol-1-, -3- and -5-yl,  
1- and 5-tetrazolyl,  
1,2,3-oxadiazol-4- and -5-yl,  
1,2,4-oxadiazol-3- and -5-yl,  
1,3,4-thiadiazol-2- and -5-yl,  
1,2,4-oxadiazol-3- and -5-yl,  
1,3,4-thiadiazol-2- and -5-yl,  
1,3,4-thiadiazol-3- and -5-yl,  
1,2,3-thiadiazol-4- and -5-yl,  
2-, 3-, 4-, 5- and 6-2H-thiopyranyl,  
2-, 3- and 4-4H-thiopyranyl,  
3- and 4-pyridazinyl, or

2-,3-pyrazinyl.

113. (New) A compound of claim 91 wherein the substituted or unsubstituted bicyclic heteroaryl groups of B and L<sup>1</sup> are, independently:

2-, 3-, 4-, 5-, 6- and 7-benzofuryl,  
2-, 3-, 4-, 5-, 6- and 7-benzothienyl,  
1-, 2-, 3-, 4-, 5-, 6- and 7-indolyl,  
1-, 2-, 4- and 5-benzimidazolyl,  
1-, 3-, 4-, 5-, 6- and 7-benzopyrazolyl,  
2-, 4-, 5-, 6- and 7-benzoxazolyl,  
3-, 4-, 5- 6- and 7-benzisoxazolyl,  
1-, 3-, 4-, 5-, 6- and 7-benzothiazolyl,  
2-, 4-, 5-, 6- and 7-benzisothiazolyl,  
2-, 4-, 5-, 6- and 7-benz-1,3-oxadiazolyl,  
2-, 3-, 4-, 5-, 6-, 7- and 8-quinolinyl,  
1-, 3-, 4-, 5-, 6-, 7-, and 8- isoquinolinyl,  
2-, 4-, 5-, 6-, 7- and 8-quinazolinyl,  
tetrahydroquinolinyl,  
tetrahydroisoquinolinyl,  
dihydrobenzofuryl,  
pyrazolo[3,4-b]pyrimidinyl,  
purinyl,  
benzodiazine,  
pterindinyl,  
pyrrolo[2,3-b]pyridinyl,  
pyrazolo[3,4-b]pyridinyl,  
oxazo[4,5-b]pyridinyl,  
imidazo[4,5-b]pyridinyl,  
cyclopentenopyridine,  
cyclohexanopyridine,  
cyclopentanopyrimidine,

cyclohexanopyrimidine,  
cyclopentanopyrazine,  
cyclohexanopyrazine,  
cyclopentanopyridiazine,  
cyclohexanopyridazine,  
cyclopentanoimidazole,  
cyclohexanoimidazole,  
cyclopentanthiophen or  
cyclohexanthiophene.

114. (New) A method of claim 91 wherein the substituted 5 and 6 membered monocyclic heteroaryl moieties of B, L and L<sup>1</sup> are independently

5-methyl-2-thienyl,  
4-methyl-2-thienyl,  
1-methyl-3-pyrolyl,  
1-methyl-3-pyrazolyl,  
5-methyl-2-thiazolyl, or  
5-methyl-1,2,4-thiadiazol-2-yl; or

the substituted phenyl and naphthyl groups of B, L and L<sup>1</sup> are independently

tetrahydronaphthyl,  
indanyl,  
indenyl,  
benzocyclobutanyl,  
benzocycloheptanyl or  
benzocycloheptenyl;

the partially saturated monocyclic heterocyclic moieties of B, L and L<sup>1</sup> are independently:

dihydropyranyl,  
dihydrofuranyl,  
dihydrothienyl,

dihydropiperidinyl or  
dihydropyrimidinyl.

115. (New) A method of claim 91 wherein the structures of B, L and L<sup>1</sup> are each,  
phenyl, furyl,  
oxadiazolyl, oxazolyl, isooxazolyl,  
pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl,  
tetrazolyl,  
thiadiazolyl, thiazolyl or thienyl and  
the structures of B and L<sup>1</sup> are additionally naphthyl, isoindolinyl, quinolinyl or  
isoquinolinyl.

116. (New) A method of claim 115 wherein the substituents of the substituted structures  
of L are methyl, trifluoromethyl, ethyl, n-propyl, n-butyl, n-pentyl, i-propyl, t-butyl, methoxy,  
ethoxy, propoxy, Cl, Br, F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino,  
ethylamino or diethylamino.

117. (New) A method of claim 115 wherein the substituents of the substituted  
structures of B and L<sup>1</sup> are methyl, trifluoromethyl, ethyl, n-propyl, n-butyl, n-pentyl, isopropyl,  
*tert*-butyl, *sec*-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, propoxy,  
Cl, Br and F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino or  
diethylamino.

118. (New) A method of claim 115 wherein the substituents of the substituted structures  
of B and L<sup>1</sup> are each, independently, selected from the group consisting of phenyl, pyridinyl,  
pyrimidinyl, chlorophenyl, dichlorophenyl, bromophenyl, dibromophenyl, chloropyridinyl,  
bromopyridinyl, dichloropyridinyl, dibromopyridinyl, methylphenyl, methylpyridinyl, quinolinyl,  
isoquinolinyl, isoindolinyl, pyrazinyl, pyridazinyl, pyrrolinyl, imidazolinyl, thienyl, furyl,

isoxazoliny, isothiazoliny, benzopyridiny, benzothiazoly,

C<sub>1</sub>-C<sub>5</sub> acyl;

NH(C<sub>1</sub>-C<sub>5</sub> alkyl, phenyl or pyridiny);

N(C<sub>1</sub>-C<sub>5</sub> alkyl)(C<sub>1</sub>-C<sub>5</sub> alkyl, phenyl or pyridiny);

N(C<sub>1</sub>-C<sub>3</sub> alkyl) SO<sub>2</sub>(C<sub>1</sub>-C<sub>5</sub> alkyl);

CO(C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl);

C(O)H;

C(O)O(C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl);

C(O)OH;

C(O)NH<sub>2</sub> ;

C(O)NH(C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl) ;

C(O)N(C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl)(C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl or pyridiny);

C(NCH<sub>3</sub>)CH<sub>3</sub>;

NHC(O)(C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl) or

N(C<sub>1</sub>-C<sub>5</sub> alkyl,)C(O)(C<sub>1</sub>-C<sub>5</sub> alkyl).

119. (New) A method as in claim 91 wherein B, L and L<sup>1</sup> of the compound of Formula I or the pharmaceutically acceptable salt thereof follow one of the following of combinations:

B= phenyl, L=phenyl and L<sup>1</sup> is phenyl, pyridiny, quinoliny or isoquinoliny,

B= phenyl, L=pyridiny and L<sup>1</sup> is phenyl, pyridiny, quinoliny or isoquinoliny,

B=phenyl, L = naphthyl and L<sup>1</sup> is phenyl, pyridiny, quinoliny or isoquinoliny,

B=pyridiny, L= phenyl and L<sup>1</sup> is phenyl, pyridiny, quinoliny or isoquinoliny,

B=pyridiny, L= pyridiny and L<sup>1</sup> is phenyl, pyridiny, quinoliny or isoquinoliny,

B =isoquinoliny, L= phenyl and L<sup>1</sup> is phenyl, pyridiny, quinoliny or isoquinoliny,

B= isoquinoliny, L= pyridiny and L<sup>1</sup> is phenyl, pyridiny, quinoliny or isoquinoliny,

B= quinoliny, L= phenyl and L<sup>1</sup> is phenyl, pyridiny, quinoliny or isoquinoliny, or

B= quinoliny, L= pyridiny and L<sup>1</sup> is phenyl, pyridiny, quinoliny or isoquinoliny.

120. (New) A method as in claim 119 wherein the pharmaceutically acceptable salt is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

121. (New) A method for the treatment of a raf mediated disorder in a human or other mammal, comprising administering to a human or other mammal in need thereof, a pharmaceutical composition comprising a tosylate salt of

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea or

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.--